Aptorum Group Ltd Class A (APM)

4.920 +0.330 (+7.19%)
Close USD Disclaimer
4.800 -0.120 (-2.439%)

Aptorum Group Ltd Class A Company Profile

Equity Type
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.
Contact Information
London,W1S 1BN United Kingdom
44 20 8092 9299
44 20 3928 8277
Top Executives
Mirko Scherer 54 2017 Independent Non-Executive Director
Chung Yuen Huen 43 2023 Founder, CEO & Non-Executive Director
Kwei-Hang Chan 76 2018 Member of Scientific Advisory Board
William J. Weiss 0 2020 Member of Scientific Advisory Board
Francis Szele 0 2020 Member of Scientific Advisory Board
Charles Bathurst 67 2017 Independent Non-Executive Director
Justin Wu 52 2017 Independent Non-Executive Director
Lawrence Baum 0 2020 Member of Scientific Advisory Board
Douglas W. Arner 53 2018 Independent Non-Executive Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles